Volrustomig (Anti-CTLA4 & PD-1)
Product Specifications
Synonyms
MEDI 5752
Target
CD markers
Applications
Transmembrane Transporters
Additionnal Information
Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040149-500 1x 500 µL
CD106 / VCAM1 (1.4C3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040017-100 1x 100 µL
Ep-CAM / CD326 (VU-1D9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741864-100 1x 100 µL
AMACR / p504S (Prostate Cancer Marker) (AMACR/1864), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041819-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rMOC-31), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details